Remedium Lifecare Limited has officially completed its transformation to Supha Pharmachem Limited following approval from the Ministry of Corporate Affairs. The pharmaceutical company, which specializes in Active Pharmaceutical Ingredients (APIs) and intermediates, received the Certificate of Incorporation pursuant to change of name on December 15, 2025.

Official Name Change Approval

The Office of the Central Processing Centre, Ministry of Corporate Affairs, issued the Certificate of Incorporation pursuant to change of name on December 15, 2025. The company has been officially renamed from Remedium Lifecare Limited to Supha Pharmachem Limited with effect from December 15, 2025.

Shareholder Approval Background

Prior to the official approval, shareholders had overwhelmingly supported the name change through a postal ballot, with over 97.00% approval. The special resolution was part of three key resolutions that also included important board appointments.

New Board Leadership

Alongside the name change, the company confirmed two significant board appointments:

Executive Leadership

Mr. Vignesh Laxman Gawde was appointed as Executive Director for a five-year term. Mr. Gawde holds an M.Sc. in Physical Chemistry from the Institute of Science, Mumbai University.

Board Chairman

Mr. Rambhajan Vishwakarma was appointed as Non-Executive Director and Chairman of the Board, bringing over 15 years of experience in banking product sales.

Implementation and Next Steps

The company has informed BSE Limited about the official name change and will process the necessary applications with the stock exchange. All company records and documents will be updated to reflect the new name - Supha Pharmachem Limited. As per regulatory requirements, the company must display both the old and new names at all required locations for a period of two years.

Corporate Details

The successful completion of the name change to Supha Pharmachem Limited represents a significant milestone in the company's evolution, potentially signaling a new strategic direction in the pharmaceutical industry.

Remedium Lifecare Limited , a prominent player in the healthcare sector, has reported a significant improvement in its financial performance for the quarter ended September 30, 2025. The company's unaudited consolidated financial results, approved by the Board of Directors, showcase a remarkable surge in profitability and operational efficiency.

Key Financial Highlights

Profit Surge and Operational Performance

Remedium Lifecare has demonstrated a remarkable improvement in its bottom line, with consolidated profit soaring to ₹862.34 lakhs in Q2 2025, compared to ₹464.88 lakhs in the previous quarter. This represents an impressive 85.50% quarter-on-quarter increase in net profit.

The company's revenue from operations stood at ₹11,105.82 lakhs for the quarter, showing a slight decrease of 2.04% compared to the previous quarter. Despite this marginal dip in revenue, Remedium Lifecare has managed to significantly improve its profitability, indicating enhanced operational efficiency and cost management.

Expense Management and Operational Efficiency

The company's total expenses for Q2 2025 amounted to ₹10,387.56 lakhs, down from ₹11,113.42 lakhs in the previous quarter. This reduction in expenses, coupled with stable revenue, has contributed to the substantial increase in profitability.

Balance Sheet Strength

As of September 30, 2025, Remedium Lifecare's consolidated balance sheet reflects a robust financial position:

• Total Assets: ₹1,62,318.10 lakhs
• Total Equity: ₹10,519.86 lakhs
• Current Assets: ₹1,61,731.30 lakhs

The company maintains a strong liquidity position with cash and cash equivalents of ₹131.59 lakhs.

Segment Information

Remedium Lifecare Limited continues to operate within a single business segment, as noted in their financial statement disclosures.

Note: The financial results are subject to limited review by the company's statutory auditors, as per regulatory requirements.